Hint of Benefit Seen With Blood Pressure Medicine in Steady-PD3 Trial

Hint of Benefit Seen With Blood Pressure Medicine in Steady-PD3 Trial

286064

Hint of Benefit Seen With Blood Pressure Medicine in Steady-PD3 Trial

A re-examination of blood samples from people with early Parkinson’s disease in a Phase 3 trial — in which Dynacirc, a blood pressure medication, failed to slow disease progression — found that those with higher blood levels of Dynacirc were slower to start an antiparkinson therapy and needed lower doses once they did begin treatment. These findings suggest that the trial’s failure may have been due to insufficient therapy exposure among some participants, its scientists noted. The analysis, “Isradipine…

You must be logged in to read/download the full post.